Ropes Wealth Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Ropes Wealth Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,000	Closed	-$3K	–	844
2020 Q4	$3K	Hold	1,000	–	–	﹤0.01%	620
2020 Q3	$3K	Hold	1,000	–	–	﹤0.01%	577
2020 Q2	$3K	Hold	1,000	–	–	﹤0.01%	522
2020 Q1	$4K	Hold	1,000	–	–	﹤0.01%	473
2019 Q4	$6K	Hold	1,000	–	–	﹤0.01%	498
2019 Q3	$8K	Hold	1,000	–	–	﹤0.01%	494
2019 Q2	$14K	Hold	1,000	–	–	﹤0.01%	460
2019 Q1	$5K	Hold	1,000	–	–	﹤0.01%	487
2018 Q4	$3K	Hold	1,000	–	–	﹤0.01%	480
2018 Q3	$8K	Buy	+1,000	New	+$7.68K	﹤0.01%	474

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ropes Wealth Advisors's ZYNE Position: Q1 2021 in Review

Ropes Wealth Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2021, closing a stake of 1,000 shares — an estimated $3K sold.

Ropes Wealth Advisors first reported a position in ZYNE in Q3 2018 and held it in 10 quarters. The position peaked at $14K in Q2 2019. 67 funds tracked by Wall St. Rank hold ZYNE as of Q1 2021.

Ropes Wealth Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2021 after selling out during the quarter.
Ropes Wealth Advisors sold 1,000 Zynerba Pharmaceuticals, Inc shares in Q1 2021, an estimated $3K.
Ropes Wealth Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2018 and held it in 10 quarters.
Ropes Wealth Advisors's Zynerba Pharmaceuticals, Inc position peaked at $14K in Q2 2019.
67 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2021.

Based on Ropes Wealth Advisors's 13F filing for Q1 2021, filed 12 May 2021.